Abstract
The Raf/MEK/extracellular signal-regulated kinase (ERK) pathway has a pivotal role in facilitating cell proliferation, and its deregulated activation is a central signature of many epithelial cancers. However paradoxically, sustained activity of Raf/MEK/ERK can also result in growth arrest in many different cell types. This anti-proliferative Raf/MEK/ERK signaling also has physiological significance, as exemplified by its potential as a tumor suppressive mechanism. Therefore, significant questions include in which cell types and by what mechanisms this pathway can mediate such an opposing context of signaling. Particularly, our understating of the role of ERK1 and ERK2, the focal points of pathway signaling, in growth arrest signaling is still limited. This review discusses these aspects of Raf/MEK/ ERK-mediated growth arrest signaling.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Arthan D, Hong S K, Park J I (2010). Leukemia inhibitory factor can mediate Ras/Raf/MEK/ERK-induced growth inhibitory signaling in medullary thyroid cancer cells. Cancer Lett, 297(1): 31–41
Balk S P, Knudsen K E (2008). AR, the cell cycle, and prostate cancer. Nucl Recept Signal, 6: e001
Bélanger L F, Roy S, Tremblay M, Brott B, Steff AM, Mourad W, Hugo P, Erikson R, Charron J (2003). Mek2 is dispensable for mouse growth and development. Mol Cell Biol, 23(14): 4778–4787
Bessard A, Frémin C, Ezan F, Fautrel A, Gailhouste L, Baffet G (2008). RNAi-mediated ERK2 knockdown inhibits growth of tumor cells in vitro and in vivo. Oncogene, 27(40): 5315–5325
Binétruy B, Heasley L, Bost F, Caron L, Aouadi M (2007). Concise review: regulation of embryonic stem cell lineage commitment by mitogen-activated protein kinases. Stem Cells, 25(5): 1090–1095
Boulton T G, Yancopoulos G D, Gregory J S, Slaughter C, Moomaw C, Hsu J, Cobb M H (1990). An insulin-stimulated protein kinase similar to yeast kinases involved in cell cycle control. Science, 249(4964): 64–67
Braig M, Lee S, Loddenkemper C, Rudolph C, Peters A H, Schlegelberger B, Stein H, Dörken B, Jenuwein T, Schmitt C A (2005). Oncogene-induced senescence as an initial barrier in lymphoma development. Nature, 436(7051): 660–665
Burkhard K A, Chen F, Shapiro P (2011). Quantitative analysis of ERK2 interactions with substrate proteins: roles for kinase docking domains and activity in determining binding affinity. J Biol Chem, 286(4): 2477–2485
Cagnol S, Chambard J C (2010). ERK and cell death: mechanisms of ERK-induced cell death-apoptosis, autophagy and senescence. FEBS J, 277(1): 2–21
Carson E B, McMahon M, Baylin S B, Nelkin B D (1995). Ret gene silencing is associated with Raf-1-induced medullary thyroid carcinoma cell differentiation. Cancer Res, 55(10): 2048–2052
Carson-Walter E B, Smith D P, Ponder B A, Baylin S B, Nelkin B D (1998). Post-transcriptional silencing of RET occurs, but is not required, during raf-1 mediated differentiation of medullary thyroid carcinoma cells. Oncogene, 17(3): 367–376
Casar B, Pinto A, Crespo P (2008). Essential role of ERK dimers in the activation of cytoplasmic but not nuclear substrates by ERK-scaffold complexes. Mol Cell, 31(5): 708–721
Chen J, Fujii K, Zhang L, Roberts T, Fu H (2001). Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism. Proc Natl Acad Sci USA, 98(14): 7783–7788
Cheung M, Sharma A, Madhunapantula S V, Robertson G P (2008). Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. Cancer Res, 68(9): 3429–3439
Collado M, Gil J, Efeyan A, Guerra C, Schuhmacher A J, Barradas M, Benguría A, Zaballos A, Flores J M, Barbacid M, Beach D, Serrano M (2005). Tumour biology: senescence in premalignant tumours. Nature, 436(7051): 642
Courchesne W E, Kunisawa R, Thorner J (1989). A putative protein kinase overcomes pheromone-induced arrest of cell cycling in S. cerevisiae. Cell, 58(6): 1107–1119
Courtois-Cox S, Jones S L, Cichowski K (2008). Many roads lead to oncogene-induced senescence. Oncogene, 27(20): 2801–2809
Dhillon A S, Hagan S, Rath O, Kolch W (2007). MAP kinase signaling pathways in cancer. Oncogene, 26(22): 3279–3290
Dhillon A S, Meikle S, Peyssonnaux C, Grindlay J, Kaiser C, Steen H, Shaw P E, Mischak H, Eychène A, Kolch W (2003). A Raf-1 mutant that dissociates MEK/extracellular signal-regulated kinase activation from malignant transformation and differentiation but not proliferation. Mol Cell Biol, 23(6): 1983–1993
Duhamel S, Hébert J, Gaboury L, Bouchard A, Simon R, Sauter G, Basik M, Meloche S (2012). Sef downregulation by Ras causes MEK1/2 to become aberrantly nuclear localized leading to polyploidy and neoplastic transformation. Cancer Res, 72(3): 626–635
Eblen S T, Slack-Davis J K, Tarcsafalvi A, Parsons J T, Weber M J, Catling A D (2004). Mitogen-activated protein kinase feedback phosphorylation regulates MEK1 complex formation and activation during cellular adhesion. Mol Cell Biol, 24(6): 2308–2317
Fanton C P, McMahon M, Pieper R O (2001). Dual growth arrest pathways in astrocytes and astrocytic tumors in response to Raf-1 activation. J Biol Chem, 276(22): 18871–18877
Ferrell J E Jr (1996). Tripping the switch fantastic: how a protein kinase cascade can convert graded inputs into switch-like outputs. Trends Biochem Sci, 21(12): 460–466
Fischer A M, Katayama C D, Pagès G, Pouysségur J, Hedrick S M (2005). The role of erk1 and erk2 in multiple stages of T cell development. Immunity, 23(4): 431–443
Fukuda M, Gotoh Y, Nishida E (1997). Interaction of MAP kinase with MAP kinase kinase: its possible role in the control of nucleocytoplasmic transport of MAP kinase. EMBO J, 16(8): 1901–1908
Giroux S, Tremblay M, Bernard D, Cardin-Girard J F, Aubry S, Larouche L, Rousseau S, Huot J, Landry J, Jeannotte L, Charron J (1999). Embryonic death of Mek1-deficient mice reveals a role for this kinase in angiogenesis in the labyrinthine region of the placenta. Curr Biol, 9(7): 369–372
Guégan J P, Ezan F, Gailhouste L, Langouët S, Baffet G (2013b). MEK1/2 Overactivation can Promote Growth Arrest by Mediating ERK1/2-Dependent Phosphorylation of p70S6K. J Cell Physiol: doi: 10.1002/jcp.24521
Guégan J P, Ezan F, Théret N, Langouët S, Baffet G (2013a). MAPK signaling in cisplatin-induced death: predominant role of ERK1 over ERK2 in human hepatocellular carcinoma cells. Carcinogenesis, 34(1): 38–47
Gupta R, Wajapeyee N (2013). Induction of cellular senescence by oncogenic RAS. Methods Mol Biol, 1048: 127–133
Hamilton WB, Kaji K, Kunath T (2013). ERK2 suppresses self-renewal capacity of embryonic stem cells, but is not required for multi-lineage commitment. PLoS ONE, 8(4): e60907
Hong S K, Kim J H, Lin M F, Park J I (2011). The Raf/MEK/extracellular signal-regulated kinase 1/2 pathway can mediate growth inhibitory and differentiation signaling via androgen receptor downregulation in prostate cancer cells. Exp Cell Res, 317(18): 2671–2682
Hong S K, Yoon S, Moelling C, Arthan D, Park J I (2009). Noncatalytic function of ERK1/2 can promote Raf/MEK/ERK-mediated growth arrest signaling. J Biol Chem, 284(48): 33006–33018
Hu S, Xie Z, Onishi A, Yu X, Jiang L, Lin J, Rho H S, Woodard C, Wang H, Jeong J S, Long S, He X, Wade H, Blackshaw S, Qian J, Zhu H (2009). Profiling the human protein-DNA interactome reveals ERK2 as a transcriptional repressor of interferon signaling. Cell, 139(3): 610–622
Hwang C Y, Lee C, Kwon K S (2009). Extracellular signal-regulated kinase 2-dependent phosphorylation induces cytoplasmic localization and degradation of p21Cip1. Mol Cell Biol, 29(12): 3379–3389
Kim E J, Park J I, Nelkin B D (2005). IFI16 is an essential mediator of growth inhibition, but not differentiation, induced by the leukemia inhibitory factor/JAK/STAT pathway in medullary thyroid carcinoma cells. J Biol Chem, 280(6): 4913–4920
Kortenjann M, Thomae O, Shaw P E (1994). Inhibition of v-rafdependent c-fos expression and transformation by a kinase-defective mutant of the mitogen-activated protein kinase Erk2. Mol Cell Biol, 14(7): 4815–4824
Krens S F, He S, Lamers G E, Meijer A H, Bakkers J, Schmidt T, Spaink H P, Snaar-Jagalska B E (2008). Distinct functions for ERK1 and ERK2 in cell migration processes during zebrafish gastrulation. Dev Biol, 319(2): 370–383
Kucharska A, Rushworth L K, Staples C, Morrice N A, Keyse S M (2009). Regulation of the inducible nuclear dual-specificity phosphatase DUSP5 by ERK MAPK. Cell Signal, 21(12): 1794–1805
Lawrence M C, Jivan A, Shao C, Duan L, Goad D, Zaganjor E, Osborne J, McGlynn K, Stippec S, Earnest S, Chen W, Cobb MH (2008). The roles of MAPKs in disease. Cell Res, 18(4): 436–442
Lefloch R, Pouysségur J, Lenormand P (2008). Single and combined silencing of ERK1 and ERK2 reveals their positive contribution to growth signaling depending on their expression levels. Mol Cell Biol, 28(1): 511–527
Lin A W, Barradas M, Stone J C, van Aelst L, Serrano M, Lowe S W (1998). Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev, 12(19): 3008–3019
Mabry M, Nakagawa T, Baylin S, Pettengill O, Sorenson G, Nelkin B (1989). Insertion of the v-Ha-ras oncogene induces differentiation of calcitonin-producing human small cell lung cancer. J Clin Invest, 84(1): 194–199
Mansour S J, Candia J M, Gloor K K, Ahn N G (1996). Constitutively active mitogen-activated protein kinase kinase 1 (MAPKK1) and MAPKK2 mediate similar transcriptional and morphological responses. Cell Growth Differ, 7(2): 243–250
McCubrey J A, Steelman L S, Chappell W H, Abrams S L, Montalto G, Cervello M, Nicoletti F, Fagone P, Malaponte G, Mazzarino M C, Candido S, Libra M, Bäsecke J, Mijatovic S, Maksimovic-Ivanic D, Milella M, Tafuri A, Cocco L, Evangelisti C, Chiarini F, Martelli A M (2012). Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget, 3(9): 954–987
McDuff F K, Turner S D (2011). Jailbreak: oncogene-induced senescence and its evasion. Cell Signal, 23(1): 6–13
Mebratu Y, Tesfaigzi Y (2009). How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer? Cell Cycle, 8(8): 1168–1175
Michaloglou C, Vredeveld L C, Soengas M S, Denoyelle C, Kuilman T, van der Horst C M, Majoor D M, Shay J W, Mooi W J, Peeper D S (2005). BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature, 436(7051): 720–724
Mooi WJ, Peeper D S (2006). Oncogene-induced cell senescence-halting on the road to cancer. N Engl J Med, 355(10): 1037–1046
Nadeau V, Guillemette S, Bélanger L F, Jacob O, Roy S, Charron J (2009). Map2k1 and Map2k2 genes contribute to the normal development of syncytiotrophoblasts during placentation. Development, 136(8): 1363–1374
Nakagawa T, Mabry M, de Bustros A, Ihle J N, Nelkin B D, Baylin S B (1987). Introduction of v-Ha-ras oncogene induces differentiation of cultured human medullary thyroid carcinoma cells. Proc Natl Acad Sci USA, 84(16): 5923–5927
Olsen C L, Gardie B, Yaswen P, Stampfer M R (2002). Raf-1-induced growth arrest in human mammary epithelial cells is p16-independent and is overcome in immortal cells during conversion. Oncogene, 21(41): 6328–6339
Pagès G, Guérin S, Grall D, Bonino F, Smith A, Anjuere F, Auberger P, Pouysségur J (1999). Defective thymocyte maturation in p44 MAP kinase (Erk 1) knockout mice. Science, 286(5443): 1374–1377
Pagès G, Lenormand P, L’Allemain G, Chambard J C, Meloche S, Pouysségur J (1993). Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation. Proc Natl Acad Sci USA, 90(18): 8319–8323
Park J I, Powers J F, Tischler A S, Strock C J, Ball D W, Nelkin B D (2005b). GDNF-induced leukemia inhibitory factor can mediate differentiation via the MEK/ERK pathway in pheochromocytoma cells derived from nf1-heterozygous knockout mice. Exp Cell Res, 303(1): 79–88
Park J I, Strock C J, Ball D W, Nelkin B D (2003). The Ras/Raf/MEK/extracellular signal-regulated kinase pathway induces autocrineparacrine growth inhibition via the leukemia inhibitory factor/JAK/STAT pathway. Mol Cell Biol, 23(2): 543–554
Park J I, Strock C J, Ball DW, Nelkin B D (2005a). Interleukin-1beta can mediate growth arrest and differentiation via the leukemia inhibitory factor/JAK/STAT pathway in medullary thyroid carcinoma cells. Cytokine, 29(3): 125–134
Pearson G, Robinson F, Beers Gibson T, Xu B E, Karandikar M, Berman K, Cobb M H (2001). Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev, 22(2): 153–183
Pinchot S N, Kunnimalaiyaan M, Sippel R S, Chen H (2009). Medullary thyroid carcinoma: targeted therapies and future directions. J Oncol, 2009: 183031
Pritchard C A, Samuels M L, Bosch E, McMahon M (1995). Conditionally oncogenic forms of the A-Raf and B-Raf protein kinases display different biological and biochemical propertie s in NIH 3T3 cells. Mol Cell Biol, 15(11): 6430–6442
Radtke S, Milanovic M, Rossé C, De Rycker M, Lachmann S, Hibbert A, Kermorgant S, Parker P J (2013). ERK2 but not ERK1 mediates HGF-induced motility in non-small cell lung carcinoma cell lines. J Cell Sci, 126(Pt 11): 2381–2391
Ravi R K, McMahon M, Yangang Z, Williams J R, Dillehay L E, Nelkin B D, Mabry M (1999b). Raf-1-induced cell cycle arrest in LNCaP human prostate cancer cells. J Cell Biochem, 72(4): 458–469
Ravi R K, Thiagalingam A, Weber E, McMahon M, Nelkin B D, Mabry M (1999a). Raf-1 causes growth suppression and alteration of neuroendocrine markers in DMS53 human small-cell lung cancer cells. Am J Respir Cell Mol Biol, 20(4): 543–549
Ravi R K, Weber E, McMahon M, Williams J R, Baylin S, Mal A, Harter M L, Dillehay L E, Claudio P P, Giordano A, Nelkin B D, Mabry M (1998). Activated Raf-1 causes growth arrest in human small cell lung cancer cells. J Clin Invest, 101(1): 153–159
Robbins D J, Zhen E, Owaki H, Vanderbilt C A, Ebert D, Geppert T D, Cobb M H (1993). Regulation and properties of extracellular signalregulated protein kinases 1 and 2 in vitro. J Biol Chem, 268(7): 5097–5106
Roberts P J, Der C J (2007). Targeting the Raf-MEK-ERK mitogenactivated protein kinase cascade for the treatment of cancer. Oncogene, 26(22): 3291–3310
Rodríguez J, Calvo F, González J M, Casar B, Andrés V, Crespo P (2010). ERK1/2 MAP kinases promote cell cycle entry by rapid, kinase-independent disruption of retinoblastoma-lamin A complexes. J Cell Biol, 191(5): 967–979
Rodríguez J, Crespo P (2011). Working without kinase activity: phosphotransfer-independent functions of extracellular signal-regulated kinases. Sci Signal, 4(196): re3
Roper E, Weinberg W, Watt F M, Land H (2001). p19ARF-independent induction of p53 and cell cycle arrest by Raf in murine keratinocytes. EMBO Rep, 2(2): 145–150
Roskoski R Jr (2012). ERK1/2 MAP kinases: structure, function, and regulation. Pharmacol Res, 66(2): 105–143
Rossomando A J, Wu J, Michel H, Shabanowitz J, Hunt D F, Weber MJ, Sturgill T W (1992). Identification of Tyr-185 as the site of tyrosine autophosphorylation of recombinant mitogen-activated protein kinase p42mapk. Proc Natl Acad Sci USA, 89(13): 5779–5783
Saba-El-Leil M K, Vella F D, Vernay B, Voisin L, Chen L, Labrecque N, Ang S L, Meloche S (2003). An essential function of the mitogenactivated protein kinase Erk2 in mouse trophoblast development. EMBO Rep, 4(10): 964–968
Samuels ML, Weber MJ, Bishop JM, McMahon M (1993). Conditional transformation of cells and rapid activation of the mitogen-activated protein kinase cascade by an estradiol-dependent human raf-1 protein kinase. Mol Cell Biol, 13(10): 6241–6252
Schaeffer H J, Catling A D, Eblen S T, Collier L S, Krauss A, Weber MJ (1998). MP1: a MEK binding partner that enhances enzyma tic activation of the MAP kinase cascade. Science, 281(5383): 1668–1671
Scholl F A, Dumesic P A, Barragan D I, Harada K, Charron J, Khavari P A (2009). Selective role for Mek1 but not Mek2 in the induction of epidermal neoplasia. Cancer Res, 69(9): 3772–3778
Serrano M, Lin A W, McCurrach M E, Beach D, Lowe S W (1997). Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell, 88(5): 593–602
Shapiro P S, Whalen A M, Tolwinski N S, Wilsbacher J, Froelich-Ammon S J, Garcia M, Osheroff N, Ahn N G (1999). Extracellular signal-regulated kinase activates topoisomerase IIalpha through a mechanism independent of phosphorylation. Mol Cell Biol, 19(5): 3551–3560
Shaul Y D, Gibor G, Plotnikov A, Seger R (2009). Specific phosphorylation and activation of ERK1c by MEK1b: a unique route in the ERK cascade. Genes Dev, 23(15): 1779–1790
Shaul Y D, Seger R (2007). The MEK/ERK cascade: from signaling specificity to diverse functions. Biochim Biophys Acta, 1773(8): 1213–1226
Shin J, Yang J, Lee J C, Baek K H (2013). Depletion of ERK2 but not ERK1 abrogates oncogenic Ras-induced senescence. Cell Signal, 25(12): 2540–2547
Shin S, Dimitri C A, Yoon S O, Dowdle W, Blenis J (2010). ERK2 but not ERK1 induces epithelial-to-mesenchymal transformation via DEF motif-dependent signaling events. Mol Cell, 38(1): 114–127
Sippel R S, Carpenter J E, Kunnimalaiyaan M, Lagerholm S, Chen H (2003). Raf-1 activation suppresses neuroendocrine marker and hormone levels in human gastrointestinal carcinoid cells. Am J Physiol Gastrointest Liver Physiol, 285(2): G245–G254
Starenki D, Singh N K, Jensen D R, Peterson F C, Park J I (2013). Recombinant leukemia inhibitory factor suppresses human medullary thyroid carcinoma cell line xenografts in mice. Cancer Lett, 339(1): 144–151
Subramaniam S, Unsicker K (2010). ERK and cell death: ERK1/2 in neuronal death. FEBS J, 277: 22–29
Takahashi C, Contreras B, Iwanaga T, Takegami Y, Bakker A, Bronson R T, Noda M, Loda M, Hunt J L, Ewen M E (2006). Nras loss induces metastatic conversion of Rb1-deficient neuroendocrine thyroid tumor. Nat Genet, 38(1): 118–123
Taylor J R, Lehmann B D, Chappell W H, Abrams S L, Steelman L S, McCubrey J A (2011). Cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells. Oncotarget, 2(8): 610–626
Vaccaro A, Chen H, Kunnimalaiyaan M (2006). In-vivo activation of Raf-1 inhibits tumor growth and development in a xenograft model of human medullary thyroid cancer. Anticancer Drugs, 17(7): 849–853
Vantaggiato C, Formentini I, Bondanza A, Bonini C, Naldini L, Brambilla R (2006). ERK1 and ERK2 mitogen-activated protein kinases affect Ras-dependent cell signaling differentially. J Biol, 5(5): 14
Voisin L, Julien C, Duhamel S, Gopalbhai K, Claveau I, Saba-El-Leil M K, Rodrigue-Gervais I G, Gaboury L, Lamarre D, Basik M, Meloche S (2008). Activation of MEK1 or MEK2 isoform is sufficient to fully transform intestinal epithelial cells and induce the formation of metastatic tumors. BMC Cancer, 8(1): 337
Voisin L, Saba-El-Leil M K, Julien C, Frémin C, Meloche S (2010). Genetic demonstration of a redundant role of extracellular signalregulated kinase 1 (ERK1) and ERK2 mitogen-activated protein kinases in promoting fibroblast proliferation. Mol Cell Biol, 30(12): 2918–2932
von Thun A, Birtwistle M, Kalna G, Grindlay J, Strachan D, Kolch W, von Kriegsheim A, Norman J C (2012). ERK2 drives tumour cell migration in three-dimensional microenvironments by suppressing expression of Rab17 and liprin-β2. J Cell Sci, 125(Pt 6): 1465–1477
Wood K W, Qi H, D’Arcangelo G, Armstrong R C, Roberts T M, Halegoua S (1993). The cytoplasmic raf oncogene induces a neuronal phenotype in PC12 cells: a potential role for cellular raf kinases in neuronal growth factor signal transduction. Proc Natl Acad Sci USA, 90(11): 5016–5020
Woods D, Parry D, Cherwinski H, Bosch E, Lees E, McMahon M (1997). Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Mol Cell Biol, 17(9): 5598–5611
Wortzel I, Seger R (2011). The ERK Cascade: Distinct Functions within Various Subcellular Organelles. Genes Cancer, 2(3): 195–209
Wu P K, Hong S K, Veeranki S, Karkhanis M, Starenki D, Plaza J A, Park J I (2013). A mortalin/HSPA9-mediated switch in tumorsuppressive signaling of Raf/MEK/extracellular signal-regulated kinase. Mol Cell Biol, 33(20): 4051–4067
Wu X, Noh S J, Zhou G, Dixon J E, Guan K L (1996). Selective activation of MEK1 but not MEK2 by A-Raf from epidermal growth factor-stimulated Hela cells. J Biol Chem, 271(6): 3265–3271
Yoon S, Seger R (2006). The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors, 24(1): 21–44
Zhu J, Woods D, McMahon M, Bishop J M (1998). Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev, 12(19): 2997–3007
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Park, JI. Growth arrest signaling of the Raf/MEK/ERK pathway in cancer. Front. Biol. 9, 95–103 (2014). https://doi.org/10.1007/s11515-014-1299-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11515-014-1299-x